DECONbench: a benchmarking platform dedicated to deconvolution methods for tumor heterogeneity quantification.

Benchmarking platform Cancer Cellular heterogeneity DNA methylation Deconvolution Omics integration Transcriptome

Journal

BMC bioinformatics
ISSN: 1471-2105
Titre abrégé: BMC Bioinformatics
Pays: England
ID NLM: 100965194

Informations de publication

Date de publication:
02 Oct 2021
Historique:
received: 30 10 2020
accepted: 20 09 2021
entrez: 3 10 2021
pubmed: 4 10 2021
medline: 6 10 2021
Statut: epublish

Résumé

Quantification of tumor heterogeneity is essential to better understand cancer progression and to adapt therapeutic treatments to patient specificities. Bioinformatic tools to assess the different cell populations from single-omic datasets as bulk transcriptome or methylome samples have been recently developed, including reference-based and reference-free methods. Improved methods using multi-omic datasets are yet to be developed in the future and the community would need systematic tools to perform a comparative evaluation of these algorithms on controlled data. We present DECONbench, a standardized unbiased benchmarking resource, applied to the evaluation of computational methods quantifying cell-type heterogeneity in cancer. DECONbench includes gold standard simulated benchmark datasets, consisting of transcriptome and methylome profiles mimicking pancreatic adenocarcinoma molecular heterogeneity, and a set of baseline deconvolution methods (reference-free algorithms inferring cell-type proportions). DECONbench performs a systematic performance evaluation of each new methodological contribution and provides the possibility to publicly share source code and scoring. DECONbench allows continuous submission of new methods in a user-friendly fashion, each novel contribution being automatically compared to the reference baseline methods, which enables crowdsourced benchmarking. DECONbench is designed to serve as a reference platform for the benchmarking of deconvolution methods in the evaluation of cancer heterogeneity. We believe it will contribute to leverage the benchmarking practices in the biomedical and life science communities. DECONbench is hosted on the open source Codalab competition platform. It is freely available at: https://competitions.codalab.org/competitions/27453 .

Sections du résumé

BACKGROUND BACKGROUND
Quantification of tumor heterogeneity is essential to better understand cancer progression and to adapt therapeutic treatments to patient specificities. Bioinformatic tools to assess the different cell populations from single-omic datasets as bulk transcriptome or methylome samples have been recently developed, including reference-based and reference-free methods. Improved methods using multi-omic datasets are yet to be developed in the future and the community would need systematic tools to perform a comparative evaluation of these algorithms on controlled data.
RESULTS RESULTS
We present DECONbench, a standardized unbiased benchmarking resource, applied to the evaluation of computational methods quantifying cell-type heterogeneity in cancer. DECONbench includes gold standard simulated benchmark datasets, consisting of transcriptome and methylome profiles mimicking pancreatic adenocarcinoma molecular heterogeneity, and a set of baseline deconvolution methods (reference-free algorithms inferring cell-type proportions). DECONbench performs a systematic performance evaluation of each new methodological contribution and provides the possibility to publicly share source code and scoring.
CONCLUSION CONCLUSIONS
DECONbench allows continuous submission of new methods in a user-friendly fashion, each novel contribution being automatically compared to the reference baseline methods, which enables crowdsourced benchmarking. DECONbench is designed to serve as a reference platform for the benchmarking of deconvolution methods in the evaluation of cancer heterogeneity. We believe it will contribute to leverage the benchmarking practices in the biomedical and life science communities. DECONbench is hosted on the open source Codalab competition platform. It is freely available at: https://competitions.codalab.org/competitions/27453 .

Identifiants

pubmed: 34600479
doi: 10.1186/s12859-021-04381-4
pii: 10.1186/s12859-021-04381-4
pmc: PMC8487526
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

473

Subventions

Organisme : Université Grenoble Alpes
ID : ANR-15-IDEX-02
Organisme : EIT Health
ID : activities 19359
Organisme : EIT Health
ID : 20377

Investigateurs

N Alcala (N)
A Arnaud (A)
F Avila Cobos (F)
Luciana Batista (L)
A-F Batto (AF)
Y Blum (Y)
F Chuffart (F)
J Cros (J)
C Decamps (C)
L Dirian (L)
D Doncevic (D)
G Durif (G)
S Y Bahena Hernandez (SY)
M Jakobi (M)
R Jardillier (R)
M Jeanmougin (M)
P Jedynak (P)
B Jumentier (B)
A Kakoichankava (A)
Maria Kondili (M)
J Liu (J)
T Maie (T)
J Marécaille (J)
J Merlevede (J)
M Meylan (M)
P Nazarov (P)
K Newar (K)
K Nyrén (K)
F Petitprez (F)
C Novella Rausell (C)
M Richard (M)
M Scherer (M)
N Sompairac (N)
K Waury (K)
T Xie (T)
M-A Zacharouli (MA)

Informations de copyright

© 2021. The Author(s).

Références

Genome Biol. 2021 May 11;22(1):152
pubmed: 33975646
Cell Syst. 2016 Oct 26;3(4):346-360.e4
pubmed: 27667365
Gastroenterology. 2018 Dec;155(6):1999-2013.e3
pubmed: 30165049
Nat Commun. 2019 Mar 22;10(1):1333
pubmed: 30902996
Nat Commun. 2019 Mar 27;10(1):1393
pubmed: 30918265
Bioinformatics. 2014 May 15;30(10):1431-9
pubmed: 24451622
Nat Methods. 2020 Mar;17(3):255-258
pubmed: 32080620
Methods Mol Biol. 2020;2117:135-157
pubmed: 31960376
Genome Biol. 2017 Mar 24;18(1):55
pubmed: 28340624
Nat Commun. 2020 Nov 6;11(1):5650
pubmed: 33159064
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220
pubmed: 30718832
BMC Med Genomics. 2019 Sep 18;12(1):132
pubmed: 31533822
Genome Biol. 2021 Apr 12;22(1):102
pubmed: 33845875
BMC Bioinformatics. 2020 Jan 13;21(1):16
pubmed: 31931698
Cell Rep. 2016 Nov 15;17(8):2075-2086
pubmed: 27851969
Genome Biol. 2019 Sep 10;20(1):195
pubmed: 31506093
Genetics. 2014 Apr;196(4):973-83
pubmed: 24496008
Nat Biotechnol. 2019 May;37(5):555-560
pubmed: 30858580
Mol Syst Biol. 2011 Oct 11;7:537
pubmed: 21988833
Genome Biol. 2016 Dec 1;17(1):249
pubmed: 27908289
Bioinformatics. 2018 Jun 1;34(11):1969-1979
pubmed: 29351586
IEEE Trans Neural Netw. 1999;10(3):626-34
pubmed: 18252563
Gut. 2019 Jun;68(6):1034-1043
pubmed: 30658994
Nat Methods. 2020 Feb;17(2):147-154
pubmed: 31907445

Auteurs

Clémentine Decamps (C)

Laboratory TIMC-IMAG, UMR 5525, CNRS, Univ. Grenoble Alpes, Grenoble, France.

Alexis Arnaud (A)

Data Institute, Univ. Grenoble Alpes, Grenoble, France.

Florent Petitprez (F)

Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.

Mira Ayadi (M)

Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.

Aurélia Baurès (A)

Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.

Lucile Armenoult (L)

Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.

Sergio Escalera (S)

Universitat de Barcelona and Computer Vision Center, Barcelona, Spain.

Isabelle Guyon (I)

LISN (INRIA/CNRS), Université Paris-Saclay, Gif-sur-Yvette, France.

Rémy Nicolle (R)

Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.

Richard Tomasini (R)

INSERM U1068 CRCM, Marseille, France.

Aurélien de Reyniès (A)

Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.

Jérôme Cros (J)

Dpt of Pathology, Beaujon Hospital, Univ. Paris-INSERM U1149, Clichy, France.

Yuna Blum (Y)

Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France. yuna.blum@univ-rennes1.fr.
IGDR UMR 6290, CNRS, Université de Rennes 1, Rennes, France. yuna.blum@univ-rennes1.fr.

Magali Richard (M)

Laboratory TIMC-IMAG, UMR 5525, CNRS, Univ. Grenoble Alpes, Grenoble, France. magali.richard@univ-grenoble-alpes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH